LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

LiDCO data presented at the International Forum on Quality and Safety in Healthcare

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that clinical outcome data regarding the use of the LiDCOrapid in a quality improvement programme will be presented at the International Forum on Quality & Safety in Healthcare today at the ExCeL centre in London. Now in its 20th year, the International Forum connects over 3,000 healthcare leaders and practitioners worldwide and provides a setting for them to meet, learn, share local knowledge and recognise accomplishments in improving quality and safety for patients and communities across the world.

Dr Nial Quiney, Consultant Anaesthetist and Clinical Director Emergency Care at the Royal Surrey County Hospital has been invited to present his emergency laparotomy study* and associated quality improvement programme at the Forum. The session will highlight how to improve outcomes for patients undergoing emergency high-risk surgery. During his talk, Dr Quiney will illustrate how the principles of enhanced recovery using LiDCOrapid for the fluid and blood flow monitoring elements can be translated into a simple quality improvement programme and care bundle for patients undergoing emergency general surgery resulting in a significant reduction in the death rate.

Approximately 50,000 emergency laparotomies are carried out in the UK each year and on average 15% of these patients will die within 30 days of the surgery. There is a significant reduction in the risk-adjusted mortality of these patients using the LiDCOrapid, 5.97 more lives were saved per 100 patients treated compared with outcomes before implementation of this quality improvement programme bundle.

Commenting, Terry O'Brien, Chief Executive Officer of LiDCO, said: "Dr Quiney's presentation follows on from the study that was published in the British Journal of Surgery in November 2014. The session will give a practical overview to this prestigious international audience of how to apply an effective care bundle which will significantly reduce the worldwide high mortality rate of patients undergoing emergency surgery."

* This study was previously published in the British Journal of Surgery 2014; 10.1002/bjs.9658

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response

· guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapid v2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

*BISTM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.